Colorectal cancer is acommon cancer in the Nordic countries and 50% of the patients develop liver metastases.L iver resection may result in long term survival. Proper staging is therefore essential and CT is the standard imaging modality. We examined whether additional FDG-PET improves therapeutic management of patients with colorectal liver metastases.
(1). Forpatients with metastases restricted to the liver,l iver resection is considered the only potentially curative treatment with a5 -year survival of 25-40% (2-4). This procedure, however,has aperi-operative mortality and morbidity of 1-2% and 25-30%, respectively.Furthermore,liver resectiondoes not improve the patient's chanceofsurvival unless all tumour tissue is removed( 4). Somep atients,w ho have been deemed incurable by liver resection, can be offered other local treatments such as radiofrequency ablation, stereotacticradiotherapy or arterial chemo-embolisation, whichm ay result in down-staging of the tumour, whichsubsequentlymay be suitable for liver Therea re 15,000 new cases of colorectal cancer in Finland, Sweden, Norway,I celand, and Denmark each year (1). Twenty-five percent have synchronous liver metastases at the time of primary diagnosis and further 25% develop metachronous liver metastases resection (5). Careful pre-treatments taging of each patient is thereforecrucial.
At present, CT scanning is the most important imaging modalityfor detection of colorectalcancer metastases. Supplementary positron emission tomography scan, PET,after injection of the glucoseanalogue 2-[ 18 F]-fluoro-2-deoxy-D-glucose, FDG, is increasingly used in all fields of oncology (6). This is based on the method'sa bility to depict highly metabolic activet issues, includingc ancer (7). Regarding patients with colorectal liver metastases, PET is reported to influence the clinical management in 20-50% of thec ases,m ostlyd ue to detectiono fa dditional metastases not detectedb yC T( 8-15). However,t he management of and the basis of clinical decisions for such patients vary between institutions. Chest CT is for exampler outinely included in thed iagnostic work-up in our institution.
In this prospective clinical study we evaluated the value of FDG-PET scan supplementary to our routine diagnostic procedures. The purpose was to evaluate whether the diagnostic accuracy could be significantly improved. The study included patients who, based on standardc ontrast enhanced CT-scan and clinical evaluation, werefound suitable for local treatment of colorectal liver metastases.
PATIENTS AND METHODS

PaTiEnTs anD sTuDy DEsiGn
Between October 2003 and April2006 atotal of 54 consecutive patients wereincluded in the study.Patients who had been deemed suitablefor local treatment of colorectal liver metastases basedonCTand routine clinical decision making (CDM) wereincluded. Patients who had had liver surgery within the precedingy ear weree xcluded. The study comprised 32 men and 22 women aged 41 to 77 years (median, 64 years); 23 patients had synchronous liver metastases and 31 patients had metachronous liver metastases.
Ad iagnostic and therapeutic plan was made for each patient at weekly conferences of the Liver Tumour Board at Aarhus University Hospital, viz. am ultidisciplinary group comprising physicians from the fields of hepatology,liver surgery,radiology,PET,and oncology.The treatment plan was based on the individual case history,WHO performance status, standardl iver biochemistry,C T-scan and percutanouso rl aparoscopic ultrasound sonography, if warranted. Patients, who met the inclusion criteria for this study,wereoffered asupplementary FDG-PET examination. The PET examination was performed 1-18 days after CT,a nd the individual plan for the patient was then re-evaluated by the Liver Tumour Board, takingi nto account the result from the PET scan. It was noted for each patient if the CT-a nd PET results werec oncordant, and whether or not the clinical decision of diagnostic or therapeutic management was changed as ac onsequence of the supplementary FDG-PET (FVM and sK).
CT scanning was performed using aPhilips Brilliance64 multi-slice CT scanner (Philips Medical Systems, Eindhoven, The netherlands). scanning covered thorax and abdomen and included aseparate scanning of the liver after intravenous injection of Visipaque (Nycomed Amersham) 270m g/ml, 2m lp er kg body weight, with a7 0 seconds delay.Interslice distance was 0.6 mm ×64.
PET scanning was performed using aSiemens ECATEX-aCT HR PET tomograph (CTi/siemens, Knoxville, usa). FDG was produced at the PET Centrea pplying standard techniques and commercially availables ystems (General Electric, Uppsala,S weden). The patient fasted overnight beforethe PET scan, but was requested to drink abundant of tap water.I ne ach patient, blood glucose concentration was lower than 8mmol/L (mean, 5mmol/L). We injected 400 MBq FDG intravenously and the patient then rested for 1.5 hours to allow FDG to distribute and accumulatein malignant tissue. PET recordings covered the body from eyes to mid-thighs by moving the scanner bed in successive positions, comprising 14-cm transaxial fields of view. Scan time for each position was 11 minutes( at ransmission scan of three minutes using external 68 Ge sources followed by an emission scan of 7m inutes). Recorded data werec orrected for attenuation based on the transmission scan and for radioactive decay to start of the scan. Images werer econstructed using an iterative algorithm, resulting in three-dimensional images of the radioactivity concentrations. Each image consisted of voxels of 2.0 ×2 .0 ×3 .1 mm 3 ,and thecentral spatialresolution was 6.7 mm FWHM (full-width at half-maximum). The PET images wereexamined by two PET physicians (SK, MS) for focal areas with an average lesion-to-surrounding tissue ratio of the radioactivity concentrations higher than 2o rt he normalized radioactivity concentration, SUV,b eing 3.5 or higher (16) . The only information available for the PET physicians was that the patients fulfilled the criteria for local treatment as evaluated by our standarddiagnostic and staging work-up including abdominal and chest CT. All procedures conformed to the recommendations stated in the Declaration of Helsinkiofthe World Medical Association (1964) . The study was approved by the Ethics Committee for Aarhus County,and each patient approved the procedures.
RESULTS
In 19% (10/54) of the patients, therapeutic management was altered as adirect consequence of non-concordance between PET and CT (Tables 1-3 ). In another 5% (3/54) of the patients, non-concordance between the PET and CT results did not affect the therapeuticmanagement.
In 76% (41/54) of the patients, supplementary PET did not affect the diagnostic or therapeuticm anagement of the patient due to concordance with CT.
As shown in Tables1and 3, the reasons for changed therapeutic management was findings of morel iver lesions by PET than by CT in four patients, fewer or no liver lesions in three patients, and extrahepatic lesions not visible on CT in three patients (two lymph nodes and one case of local recurrence of the colorectal cancer).
Amongt he four patients with morel iver lesions found with PET than with CT,the PET findings were confirmed by histological examination of resected liver tissue in Patients ID-05 and ID-07. Follow-up CT confirmed rapid growth of liver lesions in Patient ID-09, and laparoscopic ultrasound sonography of the liver confirmed multiplel iver lesions in Patient ID-01.
In patient ID-10, biopsies from CT-lesions confirmed the negative PET findings, and close followup confirmed the negative PET results in patient ID-03. 
TABLE 1
Patients with changeddiagnostic or therapeutic strategy as aconsequence of FDG-PET.
The findings of extrahepatic lesionsby PET in three patients with no extrahepatic lesions on CT wereconfirmed by histology in each of the patients.
As shown in Table 2 , diagnostic or therapeutic management was not changedi ns pite of PET findings of lung lesions in three patients. Patient ID-11 had multiple lung metastases seen at repeated CT performed three months after liver resection.
For patient ID-12 and ID-13, therew eres till no signs of lung disease after six and 12 months, respectively.
In Patient ID-14, synchronous liver metastases weresuspected at the primary operation for ar ectal cancer,but neither CT nor PET depicted any lesions. Alaparotomy was accomplished as planned, and two 3-mm malignant liver lesions werer emoved (histology-proven). In this case, CT and PET wereboth false negative.
DISCUSSION
In the present prospective study,weinvestigated the impact of PET on the therapeutic management of a group of consecutive patients with colorectal liver metastases, suitable for local treatment based on routine CDM and CT.The CT-investigation was the best possible CT of today's standard, using 64-sliced contrast-enhancedtechnique. As adirect consequence of findings by the supplementary PET,therapeutic strategy was changed in 19% (10/54) of the patients.This is comparable with previous studies, in which PET altered the management in 18 to 39% of the patients (8-15).
In 74% of the patients, therew as concordance between PET and CT.I no ne patient (ID-05), CT failed to show liver metastases which weref ound during the primary operation for the colorectal cancer.P ET found two liver lesions in this patient, and an explorative laparotomy confirmed two large liver lesions and several minor ones.
PET resulted in cancellation of planned surgery in 6% (3/54) of the patients due to extensive liver disease. PET revealed previously undetected extra-hepatic disease in another 6% (3/54) of the patients, which resulted in extended surgery in two patients and down-staging by chemotherapy followedbyradiofrequency ablation in one patient (ID-06).T his directly improved thechanceofcurable surgery,since the surgery planned without PET might have left re-sidual tumour in these patients. In other studies, detection of unsuspected extra-hepatic metastases by PET was the main reasonfor alteredtherapeutic management of patients with colorectal cancer,a nd the major consequence was cancellation of planned surgery (8-9, 11-12, 15, 17) . The reason for this discrepancy may be that at our institution, chest CT is routinely performed when staging patients with suspected colorectal metastases. Since our study included patients deemed suitable for local treatment of colorectal liver metastases based on CT in particularly,n op atients with known lung metastases were included.
In the three patientsw ith non-concordance between CT and PET (Table 2) , CT of thorax was negative, whereas PET showed thoracic lesions.T hese lesions weres mall and considered non-specific, and it was consequently decided not to change the treatment. This decision was based on the fact that PET has alow specificity for small foci in the thoracic region (18) . In two of our patients, follow-up did not reveal progression, whereas the thirdp atient developed multiple lung metastases during follow-up. Another study (11) showed good agreement between the sensitivity of chest CT and FDG-PET,b ut unfortunately chest CT was not performed in all patients in that study.
It has recently been shown that the use of PET in pre-treatment evaluation of patients with liver metastases can substantially reduce overall costs and patient morbidity (19) . This was also found by Fernandez et al. (20) , who demonstrated a5 -year survival rate of 58% after resection of colorectal liver metastases in patients screened by pre-operative PET,c ompared to am edian 5-year survival rate of 12-41%, when using staging modalities without PET.S trasbergetal. (14) found a3-year survival rate of 77% for patients allocated for liver resection based on PET. The reduced costs and morbiditya nd the improved survival rates werem ainly ar esult of ab etter selection and planningo fp atients for surgery,a voiding surgery of patients for whom the procedurew as fu-tile. Since PET,i no ther studies, has been shown to increase both sensitivity and specificity of local recurrence or thed evelopment of hepatic ande xtra-hepatic metastases (21) (22) , we decided to let the patients benefit from the PET results by includingt he results in arevised treatment plan.
The study was conducted using aP ET camera without integrated CT.Inthe three patients with nonconcordance between PET and CT,the use of acombined PET/CT scanner might have been helpful, since this improves the interpretation of bothP ET and CT images possible due to precise alignment of metabolic active lesions (PET) to well-defined anatomic structures (CT).
in conclusion, pre-treatmentF DG-PET used supplementary to CT improved the treatment plan in one fifth of the patients with colorectal liver metastases. Consequently,P ET is now included in our standard clinical work-upofthis group of patients.
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Numbers
Moreliver lesions detected by PET than CT 4( 7.4%) Fewer/no liver lesions on PET than on CT 3( 5.6%) Extra-hepatic tumour detected by PET but not by CT Lymph node 2( 3.7%) Local recurrence of primary colon cancer 1( 1.8%)
TABLE 4
Impact on treatment in the cases with non-concordance between PET and CT.
Numbers surgery cancelled due to extensive disease 3( 30%) Surgery cancelled due to no disease 3( 30%) Extended surgery 3( 30%) Down-graded by chemotherapy 1( 10%)
